COVID-19

Suresh S. Ramalingam, MD, FASCO, discusses the adjustments being made in cancer care due to the rapid spread of COVID-19 and treatments under development.

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

The NCCN has published guidelines for ensuring that patients with cancer, care providers, and staff are kept as safe as possible during the COVID-19 crisis.

Shilpa Gupta, MD, shares updates from the frontlines and discusses how she is handling the COVID-19 pandemic.

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the impact of the COVID-19 outbreak on Hong Kong and explained how the implementation of early preventive safety measures may have contributed to the low incidence rate.

Florida Cancer Specialists & Research Institute recently launched telehealth services across all Florida Cancer Specialists & Research Institute sites statewide, allowing patients continued and convenient access to care, while mitigating the impact and spread of COVID-19.

When the first case of coronavirus disease 2019 was diagnosed in Washington on January 20, 2020 clinicians at Seattle Cancer Care Alliance decided to act expeditiously and unhesitatingly to minimize disease spread.

Selinexor, an FDA-approved drug for the treatment of patients with relapsed/refractory multiple myeloma, is being evaluated in a global randomized clinical trial as a potential treatment for hospitalized patients with severe COVID-19.

Joshua M. Bauml, MD, discusses challenges in providing care to patients with lung cancer in light of the COVID-19 pandemic and ongoing efforts to reduce unnecessary exposure to the virus.

The first 2 patients with COVID-19 have received treatment in a phase II trial exploring the investigational agent leronlimab, a CCR5 antagonist which has been advancing through the pipeline as a treatment for patients with triple-negative breast cancer.

The SARS COVID-19 virus pandemic came out of nowhere, circling the globe with shocking speed and with a vengeance.

Experts from The Ohio State University Comprehensive Cancer Center–The James as well as Blanchard Valley Health System discussed the impact of the COVID-19 pandemic on cancer care.

In part 6 of our weekly COVID-19 Webinar Series, our panel of experts will share the latest updates and insights on the novel coronavirus. Join us Wednesday, April 29, 2020 at 8 PM EST.

An expert panel of oncologists addresses the oncology community’s response to the COVID-19 crisis.

The oncology supportive care agent tocilizumab might effectively treat cytokine storm caused by COVID-19 in patients with blood cancers, according to a case study of a patient with multiple myeloma.

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).

The oncology drug ruxolitinib is being explored in the planned phase III RUXCOVID trial as a treatment for cytokine storm in patients with COVID-19.

Hossein Borghaei, DO, MS, discusses the impact of COVID-19 on clinical practice and projected how the virus will change practice for the better in the long term.

This OncLive® webinar will focus on the impact of COVID-19 on oncology nursing care and will stream on Thursday April 23, 2020 at 8 PM EDT.

From implementing telemedical approaches to resequencing treatments, cancer centers across the nation have nimbly adapted to face the clinical challenges posed by the novel coronavirus 2019 disease.

Part 5 of our weekly COVID-19 webinar series will stream on April 22, 2020 at 8 PM.

OncLive interviewed experts at the State of the Science Summits™ in March 2020 on the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.